2 Stocks Up Over 600% in the Past 3 Years With More Room to Run

Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over this period, with the former skyrocketing 2,280% and the latter gaining 631%. These two rising stars in the biotech industry have experienced significant clinical and regulatory progress, which has fueled their growth engines. Even with these recent performances, Summit and Madrigal could have plenty more upside potential, so it's not too late to invest in them. Here's why.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool